- Comparison of DPP-4 Inhibitors
-
Kim NH, Kim SG
- KMID: 2173918
- J Korean Diabetes.
- 2013 Sep;14(3):111-119.
- doi: 10.4093/jkd.2013.14.3.111
During past several years, a novel class of antihyperglycemic agents, dipeptidyl peptidase-4 (DPP-4) inhibitors, has become one of the most important options in the management of type 2 diabetes. These... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea
-
Ha KH, Kim B, Shin HS, Lee J, Choi H, Kim HC, Kim DJ
- KMID: 2414908
- Korean Circ J.
- 2018 May;48(5):395-405.
- doi: 10.4070/kcj.2017.0324
BACKGROUND AND OBJECTIVES: To compare cardiovascular disease (CVD) risk associated with 5 different dipeptidyl peptidase-4 inhibitors (DPP-4is) in people with type 2 diabetes. METHODS: We identified 534,327 people who were newly... -
- CITED
-
- Close
- SHARE
-
- Close
- Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies
-
Son JW, Kim S
- KMID: 2174010
- Diabetes Metab J.
- 2015 Oct;39(5):373-383.
- doi: 10.4093/dmj.2015.39.5.373
Dipeptidyl peptidase 4 (DPP4) inhibitors have been touted as promising antihyperglycemic agents due to their beneficial effects on glycemia without inducing hypoglycemia or body weight gain and their good tolerability.... -
- CITED
-
- Close
- SHARE
-
- Close
